Merck & Co Inc

NYSE: MRK
$100.95
+$1.77 (+1.8%)
Real Time Data Delayed 15 Min.

MRK Articles

The top analyst upgrades, downgrades and other research calls from Wednesday include Apple, Cisco, Citigroup, Dollar General, Groupon, IBM, Merck, Ulta Beauty and UnitedHealth.
Tuesday was a crazy day for the U.S. markets, while all three of the major averages hit all-time highs the S&P 500 and Nasdaq closed down on the day. Prior to the markets opening, each of the...
GE and United Technologies were the big drags on the DJIA Tuesday, while Merck and UnitedHealth kept the index propped up.
Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints.
Boeing, Travelers, Merck, and Microsoft were among leading gainers on the DJIA Friday.
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
GE, DowDuPont, Merck, and IBM lifted the DJIA to more than 25,000 on Thursday.
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Here is a consensus forecast of each of the 30 Dow Jones Industrial stocks, including a forward 12-month consensus analyst price target and an expected 2018 total return on each.
In a year that saw the Dow add more than 24%, 5 stocks posted share price declines ranging from 1% to 45%. How did that happen?
UnitedHealth, American Express, Merck, and IBM led the DJIA to a positive finish on Thursday.
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the Dow.
With the passage of tax reform looking almost certain, and with companies continuing to prove that all-time highs in the market will not hurt spending cash on share buybacks, the continuation of...